All In Biotech

Drug Trial Radar · NCT06036836

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) With Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010)

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 163 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

163

Actual

Start

Sep 29, 2023

Primary completion

Mar 12, 2026

Study completion Mar 12, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Sep 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate pathologic complete response (pCR) rate of coformulated favezelimab/pembrolizumab (MK-4280A) or pembrolizumab as assessed by blinded central pathology review (BICR) in participants with cutaneous squamous cell carcinoma (cSCC) \[Cohort A\] and to evaluate lenvatinib in combination with coformulated favezelimab/pembrolizumab or pembrolizumab with respect to objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by investigator in participants proficient in mismatch repair (pMMR) endometrial cancer (EC) \[Cohort B\].

Conditions

  • Solid Tumor
  • Cutaneous Squamous Cell Carcinoma
  • Endometrial Cancer

Interventions

  • favezelimab/pembrolizumabBiological

    IV infusion

  • pembrolizumabBiological

    IV infusion

  • lenvatinibDrug

    Oral administration of capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Benefit Rate - Cohort ATime frame: Up to approximately 22 months
  2. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Investigator - Cohort BTime frame: Up to approximately 21 months

Locations

44 sites in 10 countries. Site status is shown where the registry gives one.

  • Yale-New Haven Hospital-Yale Cancer Center ( Site 0643)

    New Haven, Connecticut

  • Dana-Farber Cancer Institute ( Site 0642)

    Boston, Massachusetts

  • Rutgers Cancer Institute of New Jersey ( Site 0635)

    New Brunswick, New Jersey

  • Duke Cancer Institute ( Site 0641)

    Durham, North Carolina

  • Cleveland Clinic Main ( Site 0639)

    Cleveland, Ohio

  • St. Luke's University Health Network ( Site 0636)

    Bethlehem, Pennsylvania

  • UPMC Hillman Cancer Center ( Site 0644)

    Pittsburgh, Pennsylvania

  • UT Southwestern Medical Center-CRO-Simmons Comprehensive Cancer Center ( Site 0645)

    Dallas, Texas

  • St Vincent's Hospital-The Kinghorn Cancer Centre ( Site 0005)

    Darlinghurst, New South Wales, Australia

  • Royal North Shore Hospital ( Site 0008)

    St Leonards, New South Wales, Australia

  • Blacktown Hospital ( Site 0003)

    Sydney, New South Wales, Australia

  • Royal Brisbane and Women's Hospital ( Site 0002)

    Brisbane, Queensland, Australia

  • The Alfred Hospital ( Site 0004)

    Melbourne, Victoria, Australia

  • Fiona Stanley Hospital ( Site 0006)

    Murdock, Western Australia, Australia

  • Sunnybrook Research Institute ( Site 0607)

    Toronto, Ontario, Canada

  • Princess Margaret Cancer Centre ( Site 0606)

    Toronto, Ontario, Canada

  • Centre Hospitalier de l'Université de Montréal ( Site 0602)

    Montreal, Quebec, Canada

  • Jewish General Hospital ( Site 0605)

    Montreal, Quebec, Canada

  • McGill University Health Centre ( Site 0604)

    Montreal, Quebec, Canada

  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0

    Québec, Quebec, Canada

  • Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0155)

    Paris, France

  • Institut de cancérologie Strasbourg Europe (ICANS) ( Site 0153)

    Strasbourg, Alsace, France

  • CENTRE LEON BERARD ( Site 0151)

    Lyon Cedex08, Auvergne-Rhône-Alpes, France

  • Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan ( Site 0154)

    Brest, Finistere, France

  • Universitaetsklinikum Essen ( Site 0185)

    Essen, North Rhine-Westphalia, Germany

  • Universitaetsklinikum Essen-Klinik für Dermatologie, Venerologie und Allergologie ( Site 0182)

    Essen, North Rhine-Westphalia, Germany

  • Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Dermatologie ( Site 0183)

    Dresden, Saxony, Germany

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale-s.c. melanoma, immunoterapia oncologica e terapi

    Naples, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori-SC Oncologia Medica 3 - Tumori Testa-collo ( Site 025

    Milan, Lombardy, Italy

  • Hospital Sultan Ismail-Pusat Rawatan Radioterapi Dan Onkologi ( Site 0063)

    Johor Bahru, Johor, Malaysia

  • University Malaya Medical Centre ( Site 0061)

    Lembah Pantai, Kuala Lumpur, Malaysia

  • Sarawak General Hospital-Radiotherapy Unit ( Site 0062)

    Kuching, Sarawak, Malaysia

  • University Medical Center Groningen ( Site 0273)

    Groningen, Netherlands

  • Radboudumc ( Site 0274)

    Nijmegen, Gelderland, Netherlands

  • Erasmus Medisch Centrum ( Site 0272)

    Rotterdam, South Holland, Netherlands

  • Taichung Veterans General Hospital-GYNECOLOGY ( Site 0033)

    Taichung, Taiwan

  • National Cheng Kung University Hospital-Clinical Trial Center ( Site 0032)

    Tainan, Taiwan

  • National Taiwan University Hospital ( Site 0031)

    Taipei, Taiwan

  • Gulhane Egitim Arastirma Hastanesi-Onkoloji ( Site 0424)

    Ankara, Turkey (Türkiye)

  • Hacettepe Universite Hastaneleri-oncology hospital ( Site 0421)

    Ankara, Turkey (Türkiye)

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.